|
 |
Indian Active Pharmaceutical Ingredients(APIs) Industry Report, 2008-2009
|
 
India plays an important part in the global API market. The API output value of India was US $4.1 billion in 2007, with the CAGR as high as 18.81% during 2003-2007. And Indian ranks at the fourth in the world in terms of API output.
India currently has about 3000 API factories and 5,000 reagent factories, the key API producers including the Ranbaxy, Dr. Reddy, Cipla Ltd, Cadila Healthcare and Matrix. They are producing more than 400 sorts of API and around 10,000 kinds of reagents, satisfying over 90% of Indian domestic demand.
The pharmaceutical companies such as Dr.Reddy, Wockhardt and Sun Pharmaceuticals are also producing API. In the FY2007, 40% sales of Dr. Reddy were contributed by the API. Similarly, 19% revenues of Wockhardt and 18% revenues of Sun Pharmaceuticals were contributed by the API respectively.
Top Ten API Producers in India, 2007
Source: ResearchInChina
The API export of India will enjoy a rapid growth in the coming years, According to the Tata Strategic Management Group, Indian API export value will increase to US $12.75 billion in 2012 from US $3.75 billion in 2007.
This report gives an in-depth analysis of 28 Indian API Producers, including their profile, operating revenues, net profit, products, market distribution and future developments etc.
1. Overview of API Industry in India
1.1 Introduction to API
1.2 Status Quo and Prospects of Indian API Industry
2. Analysis on Major API producers in India
2.1 Alembic Ltd
2.2 Atul Ltd
2.3 Aurobindo Pharma Ltd
2.4 Cadila Healthcare Ltd
2.5 Cipla Ltd
2.6 Dr. Reddy’s Laboratories Limited
2.7 Dishman Pharmaceuticals &Chemicals Ltd
2.8 Divi's Laboratories Ltd
2.9 Elder Pharmaceuticals Ltd
2.10 FDC Ltd
2.11 Glenmark Pharmaceuticals Ltd
2.12 Hikal Ltd
2.13 Ind Swift Laboratories Ltd
2.14 IPCA Laboratories Ltd
2.15 JB Chemicals & Pharmaceuticals Ltd
2.16 Lupin Ltd
2.17 Matrix Laboratories Ltd
2.18 Merck Ltd
2.19 Orchid Chemicals & Pharmaceuticals Ltd
2.20 Pfizer Ltd
2.21 Piramal Healthcare Ltd
2.22 Ranbaxy Laboratories Ltd
2.23 Shasun Chemicals and Drugs Ltd
2.24 Sterling Biotech Ltd
2.25 Sun Pharmaceuticals Industries Ltd
2.26 Torrent Pharmaceuticals Ltd
2.27 Unichem Laboratories Ltd
2.28 Wockhardt Ltd
Global API Manufacturing 2007
Top 10 API producers in India, 2007
Revenue and net profit of Alembic，2003-2007
Financial highlight of Alembic, 2007-2008
Number of new products launched by Alembic, 2007-2008
Key products of animal-health of Alembic
Revenue and net profit of Atul，2003-2007
Market position of Pharmaceuticals and Intermediates Department of Atul
Revenue and net profit of Aurobindo, 2004-2008
financial Performance of Aurobindo,2006-2008
Sales of different drugs of Aurobindo
the operational statement of Aurobindo as at March 31,2008(by region)
Revenue and net profit of Cadila, 2004-2008
Strong brand of Cadila
Global operations of Zydus Cadila
Revenue break-up of Cadila
Research focus of Cadila
Strategies for growth momentum of Cadila
Scheme of Cadila for 2009
Revenue and net profit of Cipla, 2004-2008
Revenue and net profit of Dr. Reddy，2003-2007
Revenue from Key API Products of Dr. Reddy, 2006-2008
Consolidated Business-Wise Performance of Dr. Reddy
Geographic Mix of APIs of Dr. Reddy, 2007-2008
Revenue and net profit of Dishman，2003-2007
Revenue and net profit of Divis, 2004-2008
Revenue and net profit of Elder,2004 -2008
Products of Elder
Financial Performance of Elder，FY2006-08
Stocks and sales of finished goods of Elder
Revenue and assets of Elder,2007-2008
Revenue and net profit of FDC,2004-2008
Revenue and assets of FDC
Revenue and net profit of Glenmark, 2004-2008
Financial Performance of Glenmark
Production Lines & Regulatory Approvals of API of Glenmark
Four main business of Glenmark
Growth plans and targets for Glenmark
Key milestones planned for 2008-2010 of Glenmark
Revenue and net profit of Hikal, 2004-2008
Regulatory filing status of current Products of Hikal
Development of pharma pipeline of Hikal，1997-2005
Operational statement of Hikal
Revenue and net profit of Ind Swift, 2004-2008
Shareholding pattern of Ind Swift as on March 31,2008
Composition of export income of Ind Swift
Operating Expenses break-up of Ind Swift
Expenditure of R&D of Ind Swift
Revenue and net profit of IPCA, 2004-2008
Distribution of Shareholding of IPCA as on March 31,2008
Break-up of pharmaceutical sales of IPCA
Domestic branded formulations groupwise contribution for 2007-08 of IPCA
Continentwise exports of IPCA
Financial highlights of IPCA from 1998 to 2008
Revenue and net profit of JBCPL，2004 - 2008
JBCPL Composition of Sales (Formulations & APIs)
JBCPL Composition of Sales (Formulations & APIs)
Revenue and net profit of Lupin, 2004-2008
Products of Lupin，2008
Facilities of Lupin，2008
Products Coverage of Lupin，2008
Business model of Lupin，2008
Sales growth and revenue composition of Lupin，2007-2008
Lupin Consolidated Gross Sales by Market, 2004-2008
Lupin Consolidated Gross Sales by product, 2004-2008
Revenue Composition of Lupin in FY2007-08
Lupin Revenue of Exports by Product, 2004-2008
API Sales of Lupin in FY2007-08
API Key Markets
Strategy of Lupin，2008
Revenue and Net Profit of Matrix，2004-2008
Capacities and production of Matrix，2006-2007
Three principal products of Matrix，2007
Shareholding pattern of Matrix, 2008
Product group-wise performance of Matrix
Revenue and Net Profit of Merck，2004-2008
Pharmaceuticals products of Merck launched during 2008
Operational Performance of Merck, 2007-2008
Revenue and net profit of Orchid, 2004-2008
Products of Orchid ,2008
Product range of Orchid,2008
Global market reach of Orchid，2008
Orchid product development pipeline
Revenue and Net Profit of Pfizer, 2004-2008
Brands holding by Piramal,2009
Drug life-cycle of Piramal,2009
Global outsourcing partner,2009
Strategy of Piramal,2009
Revenue and net profit of Ranbaxy,2003-2007
Business model of Ranbaxy,2007
Global operation of Ranbaxy,2007
Europe-Key Markets of Ranbaxy,2007
Emerging markets of Ranbaxy,2007
Geographic sales split of Ranbaxy, 2007
Inorganic strategy of Ranbaxy,2007
Aspirations of Ranbaxy (2012)
Revenue and net profit of SCDL,2004 - 2008
Revenue and net profit of Sterling,2004 - 2008
Products structure of Sun Pharmaceuticals,2009
Revenue composition of Sun Pharmaceuticals,2009
Growing revenue of Sun Pharmaceuticals,2003-2007
Sustained profitability of Sun Pharmaceuticals,2003-2007
Successful acquisitions of Sun Pharmaceuticals,1995-2003
Peer comparison of Sun Pharmaceuticals,1992-2007
Strategy and approach of Sun Pharmaceuticals,2009
Revenue and net profit of Torrent, 2004-2008
Information in case of imported technology,2005-2007
Sales of Torrent Pharmaceuticals by regions,2006-2008
Revenue and net profit of Unichem,2004-2008
Comparison of power brands of Unichem,2006-2008
Shareholding pattern as on March 31, 2008
Financial highlights of Unichem,2005-2008
Revenue and net profit of Wockhardt,2003-2007
Biopharmaceuticals value chain of Wockhardt,2008
Sales Revenues and Profits of Wockhardt,1992-2007
Global operations of Wockhardt,2008
Operation transformation of Wockhardt in 1992, 2000 and 2007
Balanced portfolio of Wockhardt,2008
Eight acquisitions of Wockhardt,1997-2007
China Pharmaceutical Industry Statistics, 2000-2009 Thanks to the stimulus of new medical system reform launched by the government in 2009, the pharmaceuticals industry of China remains steady growth.
In the first half of 2009, the output of China’s c... China Antibiotic Market Report, 2008-2009 From the perspective of industrial scale, China's output and production capacity of antibiotic raw materials ranks the NO.1 in the world. In 2007, China's sales revenue of antibiotic raw materials rea... China Pharmaceutical Chain Industry Report, 2009 According to the chain drug stores ranking in China in 2009, top 100 enterprises in China pharmaceutical chain industry achieved the sales revenue of RMB57.24 billion in 2008, increasing by RMB13.33 b... China Vaccine Industry Report, 2008-2009 In the past decade, Chinese vaccine market tripled in scale. China has already become the world’s largest vaccine producer and now has 28 vaccine companies, ranking NO.1 around the globe. It can produ... US Pharmaceutical Industry Report, 2008-2009 The United States has the largest pharmaceutical industry in the world. In 2007, its pharmaceutical revenue totaled at US$ 315 billion.
Global Pharmaceutical Output Value and Profits by Region, 2007... Indian Pharmaceutical Formulations Industry Report, 2008-2009 India plays an important role in the global pharmaceutical market. In 2005, 2/5 DMFs to FDA were submitted by India. Currently, there are more than 400 kinds of API (Active Pharmaceutical Ingredient) ... Indian Active Pharmaceutical Ingredients(APIs) Industry Report, 2008-2009 India plays an important part in the global API market. The API output value of India was US $4.1 billion in 2007, with the CAGR as high as 18.81% during 2003-2007. And Indian ranks at the fourth in t... China Chemical Pharmaceutical Market Report, 2008 By the end of Aug, 2008, the total output value of China’s chemical pharmaceutical industry was CNY 273.272 billion, among which, the total output value of active pharmaceutical ingredient (API) was C... China Vaccine Market Report, 2007-2009 China is the largest vaccine producer and consumer in the world. According to the statistics of the General Administration of Customs, China's total vaccine import and export volume reached 34,846 ton... China Pharmaceutical Chain Industry Report, 2007-2008 Pharmaceutical industry is called as "eternal sunrise industry", mainly because of its sustained growth in market demand. The main factors driving the growth in market demand of China's pharmaceutical... China Animal Vaccine Industry Report, 2006-2009 On Jan. 18th of 2008, Ministry of Agriculture of the People's Republic of China and Ministry of Health of China jointly issued the document to intensify the efforts to carry out the inoculation of rab... China Chemical Pharmaceutical Industry Report, 2007 Global medicine industry maintains rapid growth continuously.Its scale has started to maintain fast growth since the middle and late in the 20th century. The total output value increased to USD 602 bi... Company Study of Guangxi Wuzhou Zhongheng Group In 2006, the company received the main business revenue of RMB 321.1685 million, of which the pharmaceutical industry accounted for 62.83%; the profit of main business reached RMB 154.1201 million and... China OTC Drug Market Report, 2007 By 2003, the global OTC drug market had reached 63 billion, and China's OTC drugs shared 5.7% of the global market, only behind North America, West Europe and Japan. In 2003, the sales value in China'... China Pharmaceutical Industry Report, 2006-2007 In Jan-Feb 2007, Product sales revenue of China pharmaceutical industry rose by 17.8% year-on-year and, the gross profits increased by 29.6% from a year earlier.
It is noteworthy that the sales of ch... China Anti-tumor Drugs Market Report, 2007 The anti-tumor drugs market operated well in 2006, and the total sales volume amounted to USD 34.6 billion, up 20.5% from a year earlier, and the growth margin ranked the first place among all the tre... Economic Operation of Pharmaceutical Industry in China, 2006 In 2006, total industrial output value of China pharmaceutical industry accumulated to RMB532.373 billion, up by 17.89% year on year. Total industrial output value of state-owned economy of pharmaceut... China Pharmaceutical Industry Report (Merger and Reorganization), 2006-2007 During the Tenth Five-Year Plan period (2001 to 2005), each indicator of the whole pharmaceutical industry greatly exceeded the scheduled; and the industrial output value, industrial added value and t...
|